# Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.

> **NCT05728008** · — · COMPLETED · sponsor: **IRCCS San Raffaele** · enrollment: 100 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** Ustekinumab
- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT05728008
- **Lead sponsor:** IRCCS San Raffaele
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-05
- **Primary completion:** 2022-06-05
- **Final completion:** 2022-07-05
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05728008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05728008, "Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05728008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*